Begin main content

Halobetasol propionate and tazarotene

Last Updated: February 7, 2020
Result type: Reports
Project Number: SR0638-000
Product Line: Common Drug Review

Generic Name: Halobetasol propionate and tazarotene

Brand Name: Duobrii

Manufacturer: Bausch Health, Canada Inc.

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1: Improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis.

Submission Type: New Combination

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openDecember 19, 2019
Call for patient input closedFebruary 14, 2020
Submission receivedJanuary 24, 2020
Submission acceptedFebruary 07, 2020
Review initiatedFebruary 10, 2020
Draft CADTH review report(s) provided to sponsor for commentApril 24, 2020
Deadline for sponsors commentsMay 05, 2020
CADTH responses on draft review report(s) provided to sponsorJune 05, 2020
Expert committee meeting (initial)June 17, 2020
Draft recommendation issuedJune 29, 2020
To
July 02, 2020